Cherry Creek Investment Advisors Inc. Makes New $209,000 Investment in Stryker Corporation $SYK

Cherry Creek Investment Advisors Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 528 shares of the medical technology company’s stock, valued at approximately $209,000.

Other hedge funds also recently bought and sold shares of the company. Mar Vista Investment Partners LLC lifted its holdings in shares of Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after purchasing an additional 8,353 shares during the last quarter. United Services Automobile Association purchased a new stake in shares of Stryker during the 1st quarter valued at $2,857,000. AXS Investments LLC lifted its holdings in shares of Stryker by 13.7% during the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Park Edge Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $679,000. Finally, Hendley & Co. Inc. lifted its holdings in shares of Stryker by 60.3% during the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after purchasing an additional 5,274 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on SYK. Rothschild Redb upgraded Stryker to a “hold” rating in a report on Thursday, September 18th. BTIG Research increased their price objective on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday, October 31st. Evercore ISI decreased their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Finally, Needham & Company LLC upped their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Price Performance

NYSE SYK opened at $362.74 on Wednesday. The stock’s fifty day moving average price is $376.79 and its 200 day moving average price is $381.24. The company has a market cap of $138.68 billion, a price-to-earnings ratio of 48.05, a PEG ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.